Results 61 to 70 of about 8,387 (243)
Frontiers in Cardiovascular Medicine, 2023 Background Myocardial ischemia is caused by epicardial coronary artery stenosis or atherosclerotic disease affecting microcirculation. Trimetazidine (TMZ), promotes glucose oxidation which optimizes cellular energy processes in ischemic conditions. Small
Ivan Ilic +8 more
semanticscholar +1 more source
Trimetazidine-Induced Parkinsonism: A Systematic Review [PDF]
Frontiers in Neurology, 2020 Importance: Trimetazidine (TMZ) is a medication given to patients with stable coronary artery disease. While it is reportedly well-tolerated, there are increasing numbers of reports of adverse events such as parkinsonism. Objectives: The purpose of this study was to systematically review the currently available literature on TMZ-induced parkinsonism ...
Anna Marielle B. Dy +5 more
openaire +3 more sources
The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson's Disease [PDF]
, 2020 Trimetazidine is contraindicated in movement disorders, however, a not negligible part of trimetazidine users is still patients with Parkinson's disease (PD). The present study aimed to objectively determine the impact of trimetazidine on the severity of
Janszky, József Vladimír +4 more
core +1 more source
International Journal of CardiologyBACKGROUND This real-world study evaluated the effectiveness and safety of an early combination of trimetazidine plus a calcium channel blocker (CCB) or β-blocker in patients with stable angina pectoris.
M. Marzilli +5 more
semanticscholar +1 more source
Health Science Reports, Volume 9, Issue 10, October 2026.ABSTRACT Background Vitiligo is a chronic autoimmune disease characterized by the progressive destruction of melanocytes, resulting in depigmented skin macules. While traditionally viewed as a cutaneous disorder driven by a specific CD8+ T cell‐mediated interferon‐γ (IFN‐γ) signature, emerging research suggests that vitiligo may be a systemic condition
Federica Papaccio +2 more
wiley +1 more source
Trimetazidine modulates AMPA/kainate receptors in rat vestibular ganglion neurons.
, 2007 International audienceTrimetazidine (1[2,3,4-trimethoxy-benzyl] piperazine, 2 HCl) is an anti-ischemic agent frequently administered as a prophylactic treatment for episodes of angina pectoris and chorioretinal disturbances.
Desmadryl, Gilles +4 more
core +1 more source
FADD Protein for the Early Diagnosis of Rheumatoid Arthritis
ACR Open Rheumatology, Volume 8, Issue 9, September 2026.Objective FADD (Fas‐Associated Death Domain) protein in patients’ serum and synovial fluid could be a biomarker of inflammation in rheumatic diseases. We tested whether the baseline serum FADD level would be a predictive factor for meeting the American College of Rheumatology (ACR)/EULAR 2010 criteria for rheumatoid arthritis (RA) in order to ...
Géraldine Falgarone +6 more
wiley +1 more source
Кардиоваскулярная терапия и профилактика, 2013 Aim. To assess the effects of the four-month trimetazidine MR therapy on the parameters of 24-hour electrocardiogram (ECG) monitoring and heart rate variability (HRV) in patients with stable coronary heart disease (CHD).Material and methods.
M. V. Novikova, M. G. Glezer
doaj +1 more source
Life Science, 2022 AIM Cyclophosphamide (CP)-induced cystitis is a challenging clinical problem involving inflammation and dysfunction of bladder. Trimetazidine (TMZ) is an anti-anginal drug with anti-oxidant and anti-inflammatory properties.
Seçkin Engin +7 more
semanticscholar +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Myocardial dysfunction is a critical cause of post‐cardiac arrest hemodynamic instability and circulatory failure that may lead to early mortality after resuscitation.
Jingru Li +5 more
doaj +1 more source